Regeneron Pharmaceuticals Inc. (REGN) announced Friday morning that EYLEA Injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity from baseline at 52 weeks compared to both Avastin and Lucentis in a comparative study.
Regeneron Pharmaceuticals gapped open sharply higher Friday and is now up 34.06 at $374.77. The stock has broken past resistance and has set a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News